Abstract: The present disclosure provides improved methods for bead beating and a bead beating system useful therefor. The bead beating system comprises a sample tube, beads, and a dry blocking agent, and methods for using the bead beating system to extract nucleic acids from cells containing the nucleic acids.

Abstract: The present disclosure provides improved methods for bead beating and a bead beating system useful therefor. The present disclosure further provides methods of using the bead beating system to extract nucleic acids from cells containing the nucleic acids.

Abstract: The present disclosure provides improved methods for bead beating and a bead beating system useful therefor. The present disclosure further provides methods of using the bead beating system to extract nucleic acids from cells containing the nucleic acids.

Abstract: The disclosure provides three-dimensional crosslinked polymer networks comprising one or more channels extending from the surface and/or near the surface of the network into the interior of the network, arrays comprising the networks, processes for making the networks, and uses of the networks and arrays.

Abstract: The present invention relates to the field of producing, identifying, and selecting biological binding molecules, e.g. in particular antibodies or fragments thereof, which selectively bind to somatically hypermutated B-cell receptors or B-cell receptor complexes. The method is used in order to select a biological binding molecule which specifically binds to a B-cell receptor having hypermutated regions as the target receptor, but not to a B-cell receptor without hypermutated regions, and is carried out in a cell-based system using immature B cells which are in the pro/pre stage and cause a ‘Triple Knockout’ of the genes for RAG2 or RAG1, Lambda5, and SLP65.

Abstract: The present invention relates to the field of production, identification and selection of biological binding molecules such as antibodies or fragments thereof, as well as to diagnostic procedures using them in the diagnosis of cancers, in particular malignant B-cell neoplasia. The binding molecules are able to selectively bind to autonomously active or autonomously activated B-cell receptors, the autonomously active or autonomously activated B-cell receptors being characterized by the presence of structural domains to which the binding molecule selectively binds and which are responsible for the autonomously active or autonomously activated state of the B-cell receptors.

Abstract: The present invention relates to the use of human anti-inflammatory peptides in the inhalatory treatment of inflammatory pulmonary diseases. The invention in particular relates to the use of vasoactive intestinal peptide, C-type natriuretic peptide, B-type natriuretic peptide, pituitary adenylate cyclase-activating peptide, adrenomedullin, alpha-melanocyte stimulating hormone, relaxin and Interferon gamma for said purposes. Advantageous features of an aerosol containing such a human anti-inflammatory peptide and a method for producing said aerosol are disclosed. The present invention further relates to a kit for inhalatory treatment of inflammatory pulmonary diseases. One aspect relates to treatment of CoViD-19 related ARDS.

Abstract: The present invention relates to the field of the production, identification and selection of biological binding molecules such as antibodies or fragments thereof, as well as to their use in the therapy and prophylaxis of cancer diseases, such as, in particular, malignant B-cell neoplasia. The binding molecules are able to selectively bind to autonomously active or autonomously activated B-cell receptors, the autonomously active or autonomously activated B-cell receptors being characterized by the presence of structural domains to which the binding molecule selectively binds and which are responsible for the autonomously active or autonomously activated state of the B-cell receptors.

Abstract: The task of the invention is therefore making available transfer capsules that are taken up by the target cell type and permanently or transiently modify the target cell, without exerting any toxic effects on the cell during this process. The solution according to the invention consists of the use of monodisperse cores, so as to produce polyelectrolyte nanocapsules having cell-specific sizes from them. The sizes for hematopoietic cells are in a range of 20-80 nm, preferably in a range of 40-60 nm. In this regard, the sizes of the particles must be in a very narrow range, so as to prevent toxic effects from occurring. In order to keep the toxicity of the nanocapsules low, it is furthermore important to remove the nanoparticles around which the capsules are built up (cores) before use. Methods in this regard are known from the state of the art (for example dissolution by means of EDTA). A further task is the stabilization of the transfer capsules.

Abstract: The present invention relates to the field of producing, identifying, and selecting biological binding molecules, e.g. in particular antibodies or fragments thereof, which selectively bind to autonomously active B-cell receptors or B-cell receptor complexes. The method is used in order to select a biological binding molecule which specifically binds to an autonomously active or autonomously activated B-cell receptor as the target receptor, but not to an inactive or non-activated B-cell receptor, and is carried out in a cell-based system using immature B cells which are in the pro/pre-stage and cause a ‘triple knockout’ of the genes for RAG2 or RAG1, lambda5, and SLP65.

Abstract: Methods of identifying homologous genomic sequences that may be present in a sample utilizing combinations of probes binding differently to genomic sequences from different organisms, arrays for distinguishing homologous genomic sequences, systems for distinguishing homologous genomic sequences, and bacteria binding probe molecules useful in the methods, arrays, and systems.

Abstract: The disclosure provides three-dimensional crosslinked polymer networks comprising one or more channels extending from the surface and/or near the surface of the network into the interior of the network, arrays comprising the networks, processes for making the networks, and uses of the networks and arrays.

Abstract: The invention relates to the field of the preparation, identification and selection of biological binding molecules such as antibodies or fragments thereof, and also the use thereof in the context of therapy and prophylaxis of cancers, such as malignant B-cell neoplasia in particular. The binding molecules are capable of selectively binding to B-cell receptors that have a light chain according to SEQ ID NO. 18.

Abstract: In a flow cytometry measurement method, an analysis medium is provided, which includes a fluid and biological cells contained therein. A labeling molecule is provided and is brought in contact with the analysis medium in such a way that the labeling molecule can bind specifically to a target structure located on the surface of the cell if the cell has said cell structure. For the individual cells, flow cytometry measured values are captured for a first and a second physical parameter. The first parameter is fluorescence radiation emitted by the labeling molecule when the labeling molecule is excited. The cells are classified on the basis of the flow cytometry measured values. A first calibrator and a second calibrator are provided, which have solid particles matching in shape, size and material. A target structure matching the target structure of the cells is immobilized on the surface of the first calibrator. The second calibrator does not have said target structure.

Abstract: The present invention relates to the field of producing, identifying, and selecting biological binding molecules, e.g. in particular antibodies or fragments thereof, which selectively bind to somatically hypermutated B-cell receptors or B-cell receptor complexes. The method is used in order to select a biological binding molecule which specifically binds to a B-cell receptor having hypermutated regions as the target receptor, but not to a B-cell receptor without hypermutated regions, and is carried out in a cell-based system using immature B cells which are in the pro/pre stage and cause a ‘Triple Knockout’ of the genes for RAG2 or RAG1, Lambda5, and SLP65.

Abstract: The invention relaters to a microparticle for bioanalytical investigations and a method for its production. The microparticle is suitable for being transported through a flow cell of a flow cytometer in a fluid stream. The microparticle has a solid particle core and at least one nucleic acid sense biomolecule that is binding-specific for an antisense biomolecule. A layer composed of a water-soluble conjugate is arranged on the particle core, which layer includes at least one linear polymer and/or copolymer, which has at least one first group, by means of which the polymer and/or copolymer can be cross-linked by means of irradiation with an optical radiation having a discrete wavelength, has at least one second group, to which the at least one nucleic acid sense biomolecule is conjugated, and has at least one third group that is bound to the surface of the particle core by way of a functional linker group, wherein the linker group is not capable of binding to the at least one nucleic acid sense biomolecule.

Abstract: The present disclosure provides improved methods for bead beating and a bead beating system useful therefor. The present disclosure further provides methods of using the bead beating system to extract nucleic acids from cells containing the nucleic acids.

Abstract: The disclosure provides three-dimensional cross-linked polymer networks transport channels, arrays comprising the networks, processes for making the networks, and uses of the networks and arrays.

Abstract: The present disclosure provides improved methods for bead beating and a bead beating system useful therefor. The bead beating system comprises a sample tube, beads, and a dry blocking agent, and methods for using the bead beating system to extract nucleic acids from cells containing the nucleic acids.

Abstract: A sampling device for taking samples from a gaseous beverage under pressure includes a connection for a beverage line, a pump having a pump chamber, a particle filter, a discharging opening for a beverage sample, an outlet for waste, a control device, and a line system connected to the pump chamber with adjustable valves. The sampling device is configured so a beverage sample with a volume smaller than the volume of the pump chamber is introduced from the connection into the pump chamber. The pump chamber is then separated from the connection and is expanded so gas exits from the beverage sample. The pump chamber is then connected to the outlet opening and compressed so gas which has passed out of the beverage sample is displaced. Then, the pump chamber is connected to the discharging opening via the particle filter and compressed so the beverage sample is displaced.